{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:29:22Z","timestamp":1787923762951,"version":"build-2784847793"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.msard.2026.107393","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:33:16Z","timestamp":1784043196000},"page":"107393","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Modified Delphi consensus on the use of cladribine tablets in relapsing-remitting multiple sclerosis in North-West Africa"],"prefix":"10.1016","volume":"113","author":[{"given":"Smail","family":"Daoudi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houyam","family":"Tibar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chokri","family":"Mhiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Toubal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faouzi","family":"Belahcene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riadh","family":"Gouider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Makhlouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fouzia","family":"Djebari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Taha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6842-5609","authenticated-orcid":false,"given":"Maya","family":"Zeineddine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassem","family":"Yamout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Theme","key":"10.1016\/j.msard.2026.107393_bib0001","doi-asserted-by":"crossref","first-page":"T13","DOI":"10.7224\/1537-2073.2024-080","article-title":"Current practices, challenges, and future directions in multiple sclerosis management in Sub-Saharan Africa","volume":"27","author":"Aderinto","year":"2024","journal-title":"Int. J. MS. Care"},{"key":"10.1016\/j.msard.2026.107393_bib0004","article-title":"Safety and effectiveness of Cladribine tablets after treatment with Natalizumab (CLADRINA) trial \u2013 Interim analysis","author":"AO","year":"2024","journal-title":"ACTRIMS; West Palm Beach, Florida, USA"},{"key":"10.1016\/j.msard.2026.107393_bib0005","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.vhri.2021.03.007","article-title":"Economic evaluation of cladribine tablets in patients with high disease activity-relapsing-remitting multiple sclerosis in the Kingdom of Saudi Arabia","volume":"25","author":"Bohlega","year":"2021","journal-title":"Value Health Reg. Issues."},{"key":"10.1016\/j.msard.2026.107393_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104951","article-title":"Real-world use of cladribine tablets (completion rates and treatment persistence) in patients with multiple sclerosis in England: the CLARENCE study","volume":"79","author":"Brownlee","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107393_bib0007","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.msard.2018.11.021","article-title":"Safety of cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis","volume":"29","author":"Cook","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"Theme","key":"10.1016\/j.msard.2026.107393_bib0008","article-title":"Multiple sclerosis in the middle East and North Africa","volume":"27","author":"Costa","year":"2025","journal-title":"Perspectives and Challenges"},{"issue":"10","key":"10.1016\/j.msard.2026.107393_bib0009","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1007\/s00415-022-11193-w","article-title":"Early use of high-efficacy disease\u2011modifying therapies makes the difference in people with multiple sclerosis: an expert opinion","volume":"269","author":"Filippi","year":"2022","journal-title":"J. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2026.107393_bib0010","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1177\/13524585231161494","article-title":"Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY\/CLARITY extension cohort of CLASSIC-MS: an ambispective study","volume":"29","author":"Giovannoni","year":"2023","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.msard.2026.107393_bib0011","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.msard.2026.107393_bib0013","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2026.107393_bib0012","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s40120-022-00339-7","article-title":"Cladribine tablets for relapsing-remitting multiple sclerosis: a","volume":"11","author":"Giovannoni","year":"2022","journal-title":"Clinician's Rev.. Neurol Ther."},{"issue":"5","key":"10.1016\/j.msard.2026.107393_bib0014","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1001\/jamaneurol.2018.4905","article-title":"Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis","volume":"76","author":"Harding","year":"2019","journal-title":"JAMa Neurol."},{"issue":"4","key":"10.1016\/j.msard.2026.107393_bib0015","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study","volume":"19","author":"He","year":"2020","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.msard.2026.107393_bib0016","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1080\/13696998.2018.1461630","article-title":"Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England","volume":"21","author":"Hettle","year":"2018","journal-title":"J. Med. Econ."},{"issue":"9","key":"10.1016\/j.msard.2026.107393_bib0017","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials","volume":"77","author":"Kappos","year":"2020","journal-title":"JAMa Neurol."},{"key":"10.1016\/j.msard.2026.107393_bib0019","first-page":"105","article-title":"Expert consensus on the clinical use of cladribine tablets for treating relapsing multiple sclerosis in the Asia-pacific region","author":"Kim","year":"2026","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107393_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106897","article-title":"Expert consensus on the clinical use of cladribine tablets for treating relapsing multiple sclerosis in the asia-pacific region","volume":"105","author":"Kim","year":"2026","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107393_bib0020","first-page":"97","article-title":"First insights into the safety and effectiveness of additional courses with cladribine tablets under real-world conditions","author":"Kleinschnitz","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107393_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105704","article-title":"Real-world therapy management of patients with multiple sclerosis receiving cladribine tablets beyond year 4 - results from a German cladribine cohort","volume":"88","author":"Kowarik","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"24","key":"10.1016\/j.msard.2026.107393_bib0022","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.4103\/0366-6999.195475","article-title":"Development of evidence-based recommendations: implications for preparing expert consensus statements","volume":"129","author":"Kwong","year":"2016","journal-title":"Chin. Med. J. (Engl)"},{"key":"10.1016\/j.msard.2026.107393_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102572","article-title":"Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis","volume":"46","author":"Leist","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107393_bib0024","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s42466-019-0005-5","article-title":"Navigating choice in multiple sclerosis management","volume":"1","author":"Linker","year":"2019","journal-title":"Neurol. Res. Pract."},{"key":"10.1016\/j.msard.2026.107393_bib0025","first-page":"491","article-title":"Switch to oral cladribine from first line DMD in MS: 2nd interim analysis of CLAD CROSS. congress of the European Academy of neurology; 2023; Budapest, Hungary","author":"Maniscalco AK","year":"2023","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2026.107393_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104169","article-title":"Economic evaluation of cladribine tablets in high disease activity (HDA) relapsing multiple sclerosis (RMS) patients in Lebanon","volume":"67","author":"Matni","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2026.107393_bib0027","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1007\/s40120-022-00394-0","article-title":"Expert-agreed practical recommendations on the use of Cladribine","volume":"11","author":"Meca-Lallana","year":"2022","journal-title":"Neurol. Ther."},{"issue":"13","key":"10.1016\/j.msard.2026.107393_bib0028","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1080\/14656566.2022.2106783","article-title":"Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4","volume":"23","author":"Meuth","year":"2022","journal-title":"Expert. Opin. PharmacOther"},{"key":"10.1016\/j.msard.2026.107393_bib0029","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420922685","article-title":"Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS)","volume":"13","author":"Patti","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2026.107393_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2025.123727","article-title":"Efficacy and safety of Cladribine as a therapeutic option in multiple sclerosis patients over 50 years of age: a real-world study","volume":"478","author":"Piedrabuena","year":"2025","journal-title":"J. Neurol. Sci."},{"issue":"3","key":"10.1016\/j.msard.2026.107393_bib0031","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/14737167.2019.1635014","article-title":"Cost-effectiveness of cladribine tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain","volume":"20","author":"Poveda","year":"2020","journal-title":"Expert. Rev. Pharmacoecon. Outcomes. Res."},{"issue":"17","key":"10.1016\/j.msard.2026.107393_bib0032","first-page":"777","article-title":"Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and Implementation Subcommittee of the","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Am. Acad. Neurol. Neurol."},{"key":"10.1016\/j.msard.2026.107393_bib0033","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420935019","article-title":"Expert opinion on the use of cladribine tablets in clinical practice","volume":"13","author":"S\u00f8rensen","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"13","key":"10.1016\/j.msard.2026.107393_bib0034","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1177\/1352458519877810","article-title":"The long-term outcomes of CIS patients in the Barcelona inception cohort: looking back to recognize aggressive MS","volume":"26","author":"Tintore","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107393_bib0035","series-title":"41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis; September 25, 2025","article-title":"Real-world experience with Cladribine (Mavenclad) in the MSBase registry 2025","author":"vdWA","year":"2025"},{"key":"10.1016\/j.msard.2026.107393_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104959","article-title":"Barriers to accessing multiple sclerosis disease-modifying therapies in the Middle East and North Africa region: a regional survey-based study","volume":"79","author":"Zeineddine","year":"2023","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826004281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826004281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T12:49:56Z","timestamp":1787921396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826004281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":34,"alternative-id":["S2211034826004281"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107393","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modified Delphi consensus on the use of cladribine tablets in relapsing-remitting multiple sclerosis in North-West Africa","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107393","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107393"}}